EUVIMEDEUVIMED entdecken
EditorialKommentar

Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019

Julia Del Amo

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad086 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Julia Del Amo. Beteiligte Einrichtung: Division for HIV, STIs, Viral Hepatitis and TB Control, Ministry of Health, Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19, Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(See the Major Article by Lea et al. on pages 1727–34.) To theEditor—To date, 5 observational studies among unvaccinated persons with human immunodeficiency virus (PWH)—3 in Spain, 1 in South Africa, and 1 in the United States—have reported lower coronavirus disease 2019 (COVID-19) clinical severity in PWH treated with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) compared to other regimens, including those with tenofovir alafenamide (TAF)/FTC [1–6]. All but the first publication performed extensive and careful adjustments for potential confounders of the associations between antiretroviral therapy (ART) regimens and COVID-19 outcomes. The study populations were all PWH, avoiding restrictions to only those with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which could inadvertently lead to selection bias secondary to differential SARS-CoV-2 testing. No alternative explanation was identified but that of a protective effect of TDF/FTC. The protective effect of TDF/FTC is biologically plausible. In silico and some in vitro studies suggest that tenofovir partly inhibits the SARS-CoV-2 RNA-dependent RNA-polymerase (RdRp) [7–9].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Anti-HIV AgentsHIV InfectionsHumansUnited StatesTenofovirEmtricitabineHIV

Stichwörter der Autor:innen

COVID-19Tenofovirconfoundingdrug repurposingobservational studies

Substanzen

TenofovirEmtricitabineAnti-HIV Agents

Autor:innen und Institutionen

  • Division for HIV, STIs, Viral Hepatitis and TB Control, Ministry of Health, Madrid, Spain.

Zitieren

APA

Del Amo, J. (2023). Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad086

Vancouver

Del Amo J. Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad086

BibTeX
@article{DelAmo2023,
  author = {Del Amo, Julia},
  title = {Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad086}
}
Kostenlos starten →